BACKGROUND: The relation between plasma lipid levels and Alzheimer disease (AD) and vascular dementia (VaD), and the impact of drugs to lower lipid levels remains unclear. OBJECTIVE: To investigate the relation between plasma lipid levels and the risk of AD and VaD and the impact of drugs to lower lipid levels on this relationship. DESIGN AND SETTING: Cross-sectional and prospective community-based cohort studies. PARTICIPANTS: Random sample of 4316 Medicare recipients, 65 years and older, residing in northern Manhattan, NY. MAIN OUTCOME MEASURES: Vascular dementia and AD according to standard criteria. RESULTS: Elevated levels of non-high-density lipoprotein (HDL-C) and low-density lipoprotein cholesterol (LDL-C) and decreased levels of HDL-C were weak risk factors for VaD in either cross-sectional or prospective analyses. Higher levels of total cholesterol were associated with a decreased risk of incident AD after adjustment for demographics, apolipoprotein E genotype, and cardiovascular risk factors. Treatment with drugs to lower lipid levels did not change the disease risk of either disorder. CONCLUSIONS: We found a weak relation between non-HDL-C, LDL-C, and HDL-C levels and the risk of VaD. Lipid levels and the use of agents to lower them do not seem to be associated with the risk of AD.
BACKGROUND: The relation between plasma lipid levels and Alzheimer disease (AD) and vascular dementia (VaD), and the impact of drugs to lower lipid levels remains unclear. OBJECTIVE: To investigate the relation between plasma lipid levels and the risk of AD and VaD and the impact of drugs to lower lipid levels on this relationship. DESIGN AND SETTING: Cross-sectional and prospective community-based cohort studies. PARTICIPANTS: Random sample of 4316 Medicare recipients, 65 years and older, residing in northern Manhattan, NY. MAIN OUTCOME MEASURES: Vascular dementia and AD according to standard criteria. RESULTS: Elevated levels of non-high-density lipoprotein (HDL-C) and low-density lipoprotein cholesterol (LDL-C) and decreased levels of HDL-C were weak risk factors for VaD in either cross-sectional or prospective analyses. Higher levels of total cholesterol were associated with a decreased risk of incident AD after adjustment for demographics, apolipoprotein E genotype, and cardiovascular risk factors. Treatment with drugs to lower lipid levels did not change the disease risk of either disorder. CONCLUSIONS: We found a weak relation between non-HDL-C, LDL-C, and HDL-C levels and the risk of VaD. Lipid levels and the use of agents to lower them do not seem to be associated with the risk of AD.
Authors: R Scacchi; L De Bernardini; E Mantuano; T Vilardo; L M Donini; M Ruggeri; A T Gemma; R Pascone; R M Corbo Journal: Dement Geriatr Cogn Disord Date: 1998 Jul-Aug Impact factor: 2.959
Authors: J Kuusisto; K Koivisto; L Mykkänen; E L Helkala; M Vanhanen; T Hänninen; K Kervinen; Y A Kesäniemi; P J Riekkinen; M Laakso Journal: BMJ Date: 1997-10-25
Authors: Ihab Hajjar; Jeannie Schumpert; Victor Hirth; Darryl Wieland; G Paul Eleazer Journal: J Gerontol A Biol Sci Med Sci Date: 2002-07 Impact factor: 6.053
Authors: T Yoshitake; Y Kiyohara; I Kato; T Ohmura; H Iwamoto; K Nakayama; S Ohmori; K Nomiyama; H Kawano; K Ueda Journal: Neurology Date: 1995-06 Impact factor: 9.910
Authors: Bruce R Reed; Natalie L Marchant; William J Jagust; Charles C DeCarli; Wendy Mack; Helena C Chui Journal: Neurobiol Aging Date: 2011-11-10 Impact factor: 4.673
Authors: Mark W Logue; Matthew Schu; Badri N Vardarajan; John Farrell; Kathryn L Lunetta; Gyungah Jun; Clinton T Baldwin; Margaret M Deangelis; Lindsay A Farrer Journal: Neurobiol Aging Date: 2013-12-19 Impact factor: 4.673